Pharmacokinetics of Mitiperstat in Participants With Hepatic Impairment

Status:
Not yet recruiting

Trial end date:
2024-08-20

Target enrollment:

Participant gender:

This study will assess the effect of hepatic impairment on the pharmacokinetics (PK), safety and tolerability of mitiperstat.

Phase 1

AstraZeneca